BSF Enterprise PLC Kerato Ltd Partners with University of Montreal to Develop Novel Treatment for Corneal Damage

BSF the Main Market listed biotech company and owner of corneal tissue replacement company Kerato Ltd is pleased to announce that Kerato Ltd...

...has partnered with the University of Montreal to develop a novel treatment for corneal damage.

The partnership will combine Kerato's expertise in corneal tissue engineering with the University of Montreal's research in stem cell biology.

The goal of the partnership is to develop a new treatment for corneal damage that is more effective and less invasive than current treatments.

Corneal damage is a common problem that can lead to vision loss. Current treatments for corneal damage include corneal transplants and laser surgery.

However, these treatments can be expensive, invasive, and have a long recovery time.

The new treatment that is being developed by Kerato and the University of Montreal is expected to be more effective and less invasive than current treatments.

The treatment is also expected to have a shorter recovery time.

If successful, the new treatment could have a significant impact on the lives of people who suffer from corneal damage.